{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:23:26Z","timestamp":1789662206289,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.clinthera.2019.09.009","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T07:29:21Z","timestamp":1570433361000},"page":"2416-2423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Use of Paricalcitol as Adjunctive Therapy to Renin-Angiotensin-Aldosterone System Inhibition for Diabetic Nephropathy: A Systematic Review of the Literature"],"prefix":"10.1016","volume":"41","author":[{"given":"Alexandra","family":"Schuster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Al-Makki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.09.009_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11892-008-0080-4","article-title":"Vitamin D and diabetic nephropathy","volume":"8","author":"Li","year":"2008","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.clinthera.2019.09.009_bib2","series-title":"Annual Data Report: Epidemiology of Kidney Disease in the United States","year":"2016"},{"key":"10.1016\/j.clinthera.2019.09.009_bib3","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.2337\/dc18-S010","article-title":"Microvascular complications and foot care: standards of medical care in diabetes","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2019.09.009_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pcd.2018.02.001","article-title":"SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis","volume":"12","author":"Seidu","year":"2018","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.clinthera.2019.09.009_bib5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.clinthera.2019.09.009_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(98)01346-4","article-title":"Pathogenesis, prevention, and treatment of diabetic nephropathy","volume":"352","author":"Cooper","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2019.09.009_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2019.09.009_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11154-017-9422-3","article-title":"Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy","volume":"18","author":"Ilyas","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.clinthera.2019.09.009_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2016.08.022","article-title":"Mechanistic insight of diabetic nephropathy and its pharmactherapeutic targets: an update","volume":"791","author":"Bhattacharjee","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2019.09.009_bib10","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.2215\/CJN.02010309","article-title":"Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD","volume":"4","author":"Agarwal","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2019.09.009_bib13","doi-asserted-by":"crossref","first-page":"F647","DOI":"10.1152\/ajprenal.00090.2011","article-title":"Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy","volume":"302","author":"Sanchez-Nino","year":"2012","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.clinthera.2019.09.009_bib14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1161\/HYPERTENSIONAHA.114.03748","article-title":"Paricalcitol and endothelial function in chronic kidney disease trial","volume":"64","author":"Zoccali","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2019.09.009_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2011.02.044","article-title":"Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials","volume":"216","author":"Shahin","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2019.09.009_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.atherosclerosis.2012.01.031","article-title":"Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus","volume":"223","author":"Zhang","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2019.09.009_bib17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial","volume":"376","author":"De Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2019.09.009_bib18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for the systemic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.09.009_bib19","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1093\/ndt\/gft227","article-title":"Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study","volume":"28","author":"Coyne","year":"2013","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.clinthera.2019.09.009_bib20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/dme.12606","article-title":"Vitamin D analogue therapy, cardiovascular risk and kidney function in people with type 1 diabetes mellitus and diabetic nephropathy: a randomized trial","volume":"32","author":"Joergensen","year":"2015","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2019.09.009_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jdiacomp.2015.01.004","article-title":"Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease","volume":"29","author":"Thethi","year":"2015","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.clinthera.2019.09.009_bib22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/ki.2011.207","article-title":"Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on glomerular filtration rate","volume":"80","author":"Agarwal","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2019.09.009_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/0886022X.2015.1128250","article-title":"Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease","volume":"38","author":"Tiryaki","year":"2016","journal-title":"Ren Fail"},{"key":"10.1016\/j.clinthera.2019.09.009_bib24","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1681\/ASN.2012040383","article-title":"Vitamin D receptor signaling in podocytes protects against diabetic nephropathy","volume":"23","author":"Wang","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2019.09.009_bib25","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"For the VA NEPHRON-D Investigators. combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819304862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819304862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:50:57Z","timestamp":1758963057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819304862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0149291819304862"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Paricalcitol as Adjunctive Therapy to Renin-Angiotensin-Aldosterone System Inhibition for Diabetic Nephropathy: A Systematic Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}